Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

The answer is no. From the interview with Dr. Bertolino,

"What you are referring to with respect to side effects is that ZIAGEN®has demonstrated increased risk for hypersensitivity reactions in patients who have the HLA-B*5701 allele. The risk is easily mitigated for Prurisol TM through readily available screening for the HLA-B*5701 allele and eliminating the small number of patients positive for the allele from receiving Prurisol TM. This de-risking is underscored by a nearly 2,000-patients clinical study of ZIAGEN® utilizing companion diagnostics to screen for the allele that resulted in reducing immunologically-confirmed hypersensitivity reactions to zero. We're using the same methodology."

http://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

My question is whether the patient who experienced the single adverse event might have had the human leukocyte antigen subtype B*5701 (HLA-B*5701) allele???